Cytogenix (fka CYGX)

[truthhurts]

Higher positions...You're joking right?

What are they going to be "super" directors?

John Rossi and Ocampo are dead-stick directors who have consented to having their names on the Cytogenix BOD list. I don't recall either of them ever showing up to a Cytogenix shareholders meeting even once.

Explain please how these two men are going to save Cytogenix.

http://www.sec.gov/Archives/edgar/data/1005302/000112178108000252/cytogenix10q33108.htm

======================================================
Liquidity and Capital Resources

The Company has budgeted approximately $4,600,000 for operations in fiscal year 2008, of which approximately $1,500,000 has been allocated for general and administrative costs and $3,100,000 for research and development. We will require equity financing to satisfy our working capital requirements, and have, as of March 31, 2008, $140,159 of cash on hand for fiscal year 2008.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of March 31, 2008. The Company concluded that material weaknesses over internal control of financial reporting, as previously disclosed, are still in existence. Based on this evaluation our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of March 31, 2008 are not effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and within the time periods specified in Securities and Exchange Commission rules and forms.

Changes in Internal Controls

The Company is attempting to remediate its control deficiencies. Remediation of the identified material weakness in internal controls over financial reporting will be addressed and modified as needed until all necessary internal controls are implemented and operate for a period of time, are tested, and the Company and its auditors are able to conclude that such internal controls are operating effectively. The Company cannot provide assurance that these procedures will be successful in identifying material errors that may exist in the financial statements. The Company cannot make assurances that it will not identify additional material weaknesses in its internal controls over financial reporting in the future.

======================================================

There is one critical internal control that the present executive management of Cytogenix will NEVER put into place because they dare not....and that is

To tell the truth